市場調查報告書
商品編碼
1215393
全球潛伏性結核傳染病 (LTBI) 檢測市場規模調查和預測:按測試類型、最終用戶和地區分析,2022-2029 年Global Latent Tuberculosis Infection Detection Market Size study & Forecast, by Test Type, by End-User and Regional Analysis, 2022-2029 |
潛伏性結核感染是一種細菌在體內休眠而不活躍的結核感染。
通過結核菌素皮膚試驗 (TST) 檢測。 其他疾病會增加風險,例如藥物濫用、艾滋病毒和削弱免疫系統的藥物。 結核病檢測需求激增、管理疾病治療的資金增加以及老年人口增加等因素正在推動全球市場增長。
由潛伏性結核感染 (LTBI) 發展為活動性結核病的風險不斷上升正在推動全球市場需求。 據 TBFacts.org 稱,到 2021 年,估計約有 40% 的印度人會感染結核桿菌,其中大多數患有潛伏性結核病,而不是活動性結核病。 同樣,美國疾病控制與預防中心 2021 年的一份報告估計,美國有多達 1300 萬人患有潛伏性結核病感染。 因此,人群中潛伏性結核感染的高患病率正在促進市場增長。 此外,非政府組織和市場參與者開展的提高認識運動,以及政府加大治療潛伏性結核病的力度,在未來幾年創造了多種機會。 然而,缺乏系統的結核病篩查方法、缺乏適當的建議和報銷政策阻礙了整個 2022-2029 年預測期內的市場增長。
全球潛伏性結核感染檢測市場研究中考慮的主要區域是亞太地區、北美、歐洲、拉丁美洲和世界其他地區。 由於對感染早期診斷意識的提高、結核病控制的高額資金以及醫療保健設施的改善,北美在收入方面佔據了市場主導地位。 另一方面,預計亞太地區在預測期內將以最高複合年增長率增長。 新興國家的高感染率、人口增長和有利的政府舉措等因素在預測期內推動了市場增長。
這項研究的目的是揭示近年來各個細分市場和國家/地區的市場規模,並預測未來幾年的市場規模。 本報告旨在捕捉被調查國家行業的定性和定量方面的情況。
它還提供了關鍵方面的詳細信息,例如決定市場未來增長的驅動因素和挑戰。 此外,它還包含供利益相關者投資的微觀市場潛在機會,以及對主要參與者的競爭格局和產品供應的深入分析。
Global Latent Tuberculosis Infection Detection Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Latent Tuberculosis Infection (LTBI) is a variety of TB infection in which bacteria remains inactive specifically bacteria that exists in the sleeping state inside the individual's body. The detection of this infection is identified by the tuberculin skin test (TST). The risk is increased by other diseases including drug abuse, HIV, or medications that weakens the immune system. Factors such as surging demand for tuberculosis testing, growing funding to manage disease treatment, and increasing geriatric population are driving the market growth globally.
The rising risk of developing active TB from latent tuberculosis infection (LTBI) is propelling the demand for market across the globe. According to TBFacts.org, in 2021, about 40% of Indians are estimated to be infected with the TB bacteria, with the great majority having latent TB instead of active TB disease. Likewise, according to the Centers for Disease Control and Prevention report 2021, it was estimated that up to 13 million people in the United States suffered from latent TB infection. Therefore, the high prevalence rate of latent tuberculosis infection among the population is augmenting the market growth. Furthermore, growing awareness campaigns conducted by non-government bodies and market players, as well as a rising number of government initiatives to treat LTBI are leveraging multiple opportunities in the foreseen years. However, the lack of a systematic approach to screening tuberculosis and the unavailability of proper recommendations and reimbursement policies are hindering market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Latent Tuberculosis Infection Detection Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the growing awareness about early diagnosis of infection, high funding for tuberculosis management, and improvement of healthcare facilities. Whereas, Asia Pacific is expected to grow at the highest CAGR during the forecast period. Factors such as high infection rates in developing countries, increasing population, as well as government favorable initiatives are burgeoning the market growth in the forecasting years.
Major market players included in this report are:
QIAGEN N.V.
Oxford Immunotec Inc.
F. Hoffmann-La Roche Ltd.
Sanofi S.A.
Abbott Laboratories
bioMerieux SA
Becton, Dickinson, and Company
Endo International plc
PerkinElmer, Inc.
Bruker Corporation
Recent Developments in the Market:
Global Latent Tuberculosis Infection Detection Market Report Scope:
Historical Data: 2019-2020-2021
Base Year for Estimation: 2021
Forecast period: 2022-2029
Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered: Test Type, End-User, Region
Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define the market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study.
The report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Test Type:
Tuberculin Skin Test
Interferon Gamma Release Assays
By End User:
Diagnostic Laboratories
Hospitals/Clinics
Academic & Research Institutions
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
ROLA
Rest of the World
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
List of figures
List of tables and figures and dummy in nature, final lists may vary in the final deliverable